Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 in gynaecological malignancies
NCT05896020Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Jul 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in Cervical Cancer (CC), ovarian cancer, endometrial cancer (EC), sponsored by Hengrui. Started Jul 2023; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
Cervical Cancer (CC)ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT05896020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896020.